First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up

Ziqi Jia; Yanyu Wang; Lei Cao; Yadong Wang; Yang Song; Xiaoying Yang; Zhongxing Bing; Zhili Cao; Peng Liu; Shuyang Zhang; Zexin Chen; Min Huang; Yan Yu; Han Han-Zhang; Jinlei Song; Daniel C. Christoph; Antonio Passaro; Cesare Gridelli; Tomoyuki Hishida; Naixin Liang; Shanqing Li

doi:10.21037/jtd-20-1882

First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up

Ziqi Jia, Yanyu Wang, Lei Cao, Yadong Wang, Yang Song, Xiaoying Yang, Zhongxing Bing, Zhili Cao, Peng Liu, Shuyang Zhang, Zexin Chen, Min Huang, Yan Yu, Han Han-Zhang, Jinlei Song, Daniel C. Christoph, Antonio Passaro, Cesare Gridelli, Tomoyuki Hishida, Naixin LiangShanqing Li

Department of Surgery (General Thoracic Surgery)

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Original language	English
Pages (from-to)	3764-3773
Number of pages	10
Journal	Journal of Thoracic Disease
Volume	12
Issue number	7
DOIs	https://doi.org/10.21037/jtd-20-1882
Publication status	Published - 2020 Jul 1

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.21037/jtd-20-1882

Cite this

Jia, Z., Wang, Y., Cao, L., Wang, Y., Song, Y., Yang, X., Bing, Z., Cao, Z., Liu, P., Zhang, S., Chen, Z., Huang, M., Yu, Y., Han-Zhang, H., Song, J., Christoph, D. C., Passaro, A., Gridelli, C., Hishida, T., ... Li, S. (2020). First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up. Journal of Thoracic Disease, 12(7), 3764-3773. https://doi.org/10.21037/jtd-20-1882

Jia, Z, Wang, Y, Cao, L, Wang, Y, Song, Y, Yang, X, Bing, Z, Cao, Z, Liu, P, Zhang, S, Chen, Z, Huang, M, Yu, Y, Han-Zhang, H, Song, J, Christoph, DC, Passaro, A, Gridelli, C, Hishida, T, Liang, N & Li, S 2020, 'First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up', Journal of Thoracic Disease, vol. 12, no. 7, pp. 3764-3773. https://doi.org/10.21037/jtd-20-1882

@article{c5678fdfb07b4a97bb2ace0f0f403b2e,

title = "First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up",

author = "Ziqi Jia and Yanyu Wang and Lei Cao and Yadong Wang and Yang Song and Xiaoying Yang and Zhongxing Bing and Zhili Cao and Peng Liu and Shuyang Zhang and Zexin Chen and Min Huang and Yan Yu and Han Han-Zhang and Jinlei Song and Christoph, {Daniel C.} and Antonio Passaro and Cesare Gridelli and Tomoyuki Hishida and Naixin Liang and Shanqing Li",

note = "Funding Information: The authors would like to thank Huihui Xu for her contribution to clinical information collection of this research. Funding: This work was supported by the (I) Beijing Natural Science Foundation (7182132); (II) Special Data Service for Oncology, The National Population and Health Scientific Data Sharing Platform (NCMI-ABD02-201809; NCMI-YF02N-201906), Supported by Ministry of Science and Technology of the People{\textquoteright}s Republic of China (MOST); (III) Beijing Dongcheng District Science and Technology Commission Excellent Talents Project (2018-DCQYXRCXM-012); (IV) Beijing Students{\textquoteright} Platform for Innovation and Entrepreneurship Training Program (2019zlgc0629); (V) National Key Research and Development Program of China Grant (2016YFC0901500). Funding Information: The authors would like to thank Huihui Xu for her contribution to clinical information collection of this research. This work was supported by the (I) Beijing Natural Science Foundation (7182132); (II) Special Data Service for Oncology, The National Population and Health Scientific Data Sharing Platform (NCMI-ABD02-201809; NCMI-YF02N-201906), Supported by Ministry of Science and Technology of the People's Republic of China (MOST); (III) Beijing Dongcheng District Science and Technology Commission Excellent Talents Project (2018-DCQYXRCXM-012); (IV) Beijing Students' Platform for Innovation and Entrepreneurship Training Program (2019zlgc0629); (V) National Key Research and Development Program of China Grant (2016YFC0901500). Funding Information: Reporting Checklist: The authors have completed the CARE reporting checklist. Available at http://dx.doi.org/10.21037/ jtd-20-1882 Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi. org/10.21037/jtd-20-1882). ZJ reports grants from Beijing Students{\textquoteright} platform for innovation and entrepreneurship training program, during the conduct of the study. ZC reports personal fees from Accurate International Biotechnology Co. Ltd, during the conduct of the study. MH reports personal fees from Accurate International Biotechnology Co. Ltd., during the conduct of the study. YY reports personal fees from Accurate International Biotechnology Co. Ltd, during the conduct of the study. HHZ reports personal fees from Burning Rock Biotechnology Co. Ltd., during the conduct of the study. JS reports personal fees from Burning Rock Biotechnology Co. Ltd., during the conduct of the study. DCC reports personal fees, non-financial support and other from AstraZeneca, personal fees, non-financial support and other from Bayer, personal fees, non-financial support and other from Boehringer-Ingelheim, personal fees, non-financial support and other from Bristol-Myers Squibb, personal fees, non-financial support and other from Chugai, personal fees, non-financial support and other from Merck, Sharp & Dohme, personal fees, non-financial support and other from Novartis, personal fees, non-financial support and other from Pfizer, personal fees, non-financial support and other from Roche, personal fees, non-financial support and other from Takeda, outside the submitted work. AP reports personal fees from Roche, personal fees from BMS, personal fees from MSD, personal fees from Lilly, personal fees from Dako, personal fees from Astra Zeneca, outside the submitted work, and he serves as an unpaid editorial board member of Journal of Thoracic Disease from Aug 2019 to Jul 2021. CG reports personal fees from Astra Zeneca, grants and personal fees from MSD, personal fees from BMS, personal fees from Roche, personal fees from Menarini, personal fees from Novartis, outside the submitted work. NL reports grants from Beijing Natural Science Foundation, grants from Ministry of Science and Technology of the People{\textquoteright}s Republic of China (MOST), grants from Chinese Academy of Medical Sciences Young Medical Talent Award Fund, grants from Beijing Students{\textquoteright} platform for innovation and entrepreneurship training program, grants from National Key Research and Development Program of China Grant, during the conduct of the study. The other authors have no conflicts of interest to declare.",

year = "2020",

month = jul,

day = "1",

doi = "10.21037/jtd-20-1882",

language = "English",

volume = "12",

pages = "3764--3773",

journal = "Journal of Thoracic Disease",

issn = "2072-1439",

publisher = "Pioneer Bioscience Publishing Company (PBPC)",

number = "7",

}

TY - JOUR

T1 - First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up

AU - Jia, Ziqi

AU - Wang, Yanyu

AU - Cao, Lei

AU - Wang, Yadong

AU - Song, Yang

AU - Yang, Xiaoying

AU - Bing, Zhongxing

AU - Cao, Zhili

AU - Liu, Peng

AU - Zhang, Shuyang

AU - Chen, Zexin

AU - Huang, Min

AU - Yu, Yan

AU - Han-Zhang, Han

AU - Song, Jinlei

AU - Christoph, Daniel C.

AU - Passaro, Antonio

AU - Gridelli, Cesare

AU - Hishida, Tomoyuki

AU - Liang, Naixin

AU - Li, Shanqing

N1 - Funding Information: The authors would like to thank Huihui Xu for her contribution to clinical information collection of this research. Funding: This work was supported by the (I) Beijing Natural Science Foundation (7182132); (II) Special Data Service for Oncology, The National Population and Health Scientific Data Sharing Platform (NCMI-ABD02-201809; NCMI-YF02N-201906), Supported by Ministry of Science and Technology of the People’s Republic of China (MOST); (III) Beijing Dongcheng District Science and Technology Commission Excellent Talents Project (2018-DCQYXRCXM-012); (IV) Beijing Students’ Platform for Innovation and Entrepreneurship Training Program (2019zlgc0629); (V) National Key Research and Development Program of China Grant (2016YFC0901500). Funding Information: The authors would like to thank Huihui Xu for her contribution to clinical information collection of this research. This work was supported by the (I) Beijing Natural Science Foundation (7182132); (II) Special Data Service for Oncology, The National Population and Health Scientific Data Sharing Platform (NCMI-ABD02-201809; NCMI-YF02N-201906), Supported by Ministry of Science and Technology of the People's Republic of China (MOST); (III) Beijing Dongcheng District Science and Technology Commission Excellent Talents Project (2018-DCQYXRCXM-012); (IV) Beijing Students' Platform for Innovation and Entrepreneurship Training Program (2019zlgc0629); (V) National Key Research and Development Program of China Grant (2016YFC0901500). Funding Information: Reporting Checklist: The authors have completed the CARE reporting checklist. Available at http://dx.doi.org/10.21037/ jtd-20-1882 Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi. org/10.21037/jtd-20-1882). ZJ reports grants from Beijing Students’ platform for innovation and entrepreneurship training program, during the conduct of the study. ZC reports personal fees from Accurate International Biotechnology Co. Ltd, during the conduct of the study. MH reports personal fees from Accurate International Biotechnology Co. Ltd., during the conduct of the study. YY reports personal fees from Accurate International Biotechnology Co. Ltd, during the conduct of the study. HHZ reports personal fees from Burning Rock Biotechnology Co. Ltd., during the conduct of the study. JS reports personal fees from Burning Rock Biotechnology Co. Ltd., during the conduct of the study. DCC reports personal fees, non-financial support and other from AstraZeneca, personal fees, non-financial support and other from Bayer, personal fees, non-financial support and other from Boehringer-Ingelheim, personal fees, non-financial support and other from Bristol-Myers Squibb, personal fees, non-financial support and other from Chugai, personal fees, non-financial support and other from Merck, Sharp & Dohme, personal fees, non-financial support and other from Novartis, personal fees, non-financial support and other from Pfizer, personal fees, non-financial support and other from Roche, personal fees, non-financial support and other from Takeda, outside the submitted work. AP reports personal fees from Roche, personal fees from BMS, personal fees from MSD, personal fees from Lilly, personal fees from Dako, personal fees from Astra Zeneca, outside the submitted work, and he serves as an unpaid editorial board member of Journal of Thoracic Disease from Aug 2019 to Jul 2021. CG reports personal fees from Astra Zeneca, grants and personal fees from MSD, personal fees from BMS, personal fees from Roche, personal fees from Menarini, personal fees from Novartis, outside the submitted work. NL reports grants from Beijing Natural Science Foundation, grants from Ministry of Science and Technology of the People’s Republic of China (MOST), grants from Chinese Academy of Medical Sciences Young Medical Talent Award Fund, grants from Beijing Students’ platform for innovation and entrepreneurship training program, grants from National Key Research and Development Program of China Grant, during the conduct of the study. The other authors have no conflicts of interest to declare.

PY - 2020/7/1

Y1 - 2020/7/1

UR - http://www.scopus.com/inward/record.url?scp=85089395783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089395783&partnerID=8YFLogxK

U2 - 10.21037/jtd-20-1882

DO - 10.21037/jtd-20-1882

M3 - Article

AN - SCOPUS:85089395783

SN - 2072-1439

VL - 12

SP - 3764

EP - 3773

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

IS - 7

ER -

First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this